Regulus Appoints VP, Clinical Development
This article was originally published in Scrip
Regulus Therapeutics Inc., a biopharmaceutical company developing innovative medicines targeting microRNAs, has appointed Dr. Michael Huang vice-president of clinical development. At Regulus, Huang will be responsible for leading the company's global clinical operations and medical affairs and will serve as a key member of the executive leadership team. Most recently, Huang was vice-president of clinical development at Auspex Pharmaceuticals, Inc. (acquired by Teva Pharmaceutical Industries Ltd. in May 2015) and was responsible for providing project and clinical leadership across multiple programs focused on the treatment of central nervous system disorders.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.